ICCM - IceCure's ProSense Cryoablation is Determined Safe & Effective Outpatient Procedure for Breast Cancer by Independent Study

2023-10-02 08:31:38 ET

(24/7 MARKET NEWS) – IceCure Medical Ltd. (NASDAQ: ICCM) stated, this morning, that new data, from a study that was conducted in Spain with women who declined standard of care surgery, was presented at the European Society of Breast Imaging (“EUSOBI”) Scientific Meeting in Valencia, Spain by Lucía Graña-López, MD, PhD, principal investigator of the independent, non-sponsored study.

IceCure Medical is trading at $$0.83, up $0.29 (+53.64%), on 534.78K premarket shares traded.

Its 52-week range is $0.52 to $4.73. It should fill the gap to about 90-cents, has a little resistance to $1.10 and its following key inflection point is $1.20, but keep in mind that this is a foreign based listing so swing or scalp trading is best.

24/7 …

The post IceCure’s ProSense Cryoablation is Determined Safe & Effective Outpatient Procedure for Breast Cancer by Independent Study appeared first on 24/7 Market News .

For further details see: